Spinal Muscular Atrophy News and Research

RSS
Spinal muscular atrophy (SMA) is a motor neuron disease and the leading genetic cause of death among infants and toddlers. Characterized by selective loss of nerve cells in the spinal cord, the disease leads to increasing muscular weakness and atrophy. Over time, patients afflicted by SMA continue to lose muscle control and strength, leading to progressive inability to walk, stand, sit up and breathe. It is estimated that approximately 1 in 6,000 to 1 in 10,000 infants are born annually worldwide with SMA.
Researchers identify genetic cause of a rare neurological disorder

Researchers identify genetic cause of a rare neurological disorder

Genethon announces dosing of first patient at pediatric clinical trial platform for neuromuscular diseases

Genethon announces dosing of first patient at pediatric clinical trial platform for neuromuscular diseases

Keele researcher awarded prestigious grant to identify treatments for devastating childhood disease

Keele researcher awarded prestigious grant to identify treatments for devastating childhood disease

Researchers evaluate new drug for spinal muscular atrophy in a broader spectrum of patients

Researchers evaluate new drug for spinal muscular atrophy in a broader spectrum of patients

Study: Early benefit assessment of new drugs within the framework of AM-NOG procedure

Study: Early benefit assessment of new drugs within the framework of AM-NOG procedure

UC San Diego researchers launch clinical trial to test gene therapy for Alzheimer’s disease

UC San Diego researchers launch clinical trial to test gene therapy for Alzheimer’s disease

Spark Therapeutics launches gene therapy clinical trial for late-onset Pompe disease

Spark Therapeutics launches gene therapy clinical trial for late-onset Pompe disease

Canadian Neuromuscular Disease Registry increases patient access to research, clinical trials

Canadian Neuromuscular Disease Registry increases patient access to research, clinical trials

Designer DNA agent reduces myeloma stem cell abundance, lowers disease burden in mice

Designer DNA agent reduces myeloma stem cell abundance, lowers disease burden in mice

Replacing the RNA strand with DNA may enhance efficacy of ASO-based drugs

Replacing the RNA strand with DNA may enhance efficacy of ASO-based drugs

Amilorides reduce SARS-CoV-2 viral replication in vitro

Amilorides reduce SARS-CoV-2 viral replication in vitro

Genethon to start international clinical trial for treatment of Duchenne muscular dystrophy

Genethon to start international clinical trial for treatment of Duchenne muscular dystrophy

Researchers develop telomerase gene therapy for treating different pathologies

Researchers develop telomerase gene therapy for treating different pathologies

Study finds how the brain 're-wires' after neurological disease

Study finds how the brain 're-wires' after neurological disease

Study implicates new gene as driver of motor neuron diseases

Study implicates new gene as driver of motor neuron diseases

Study examines safety and early outcomes of gene therapy for spinal muscular atrophy

Study examines safety and early outcomes of gene therapy for spinal muscular atrophy

FDA approves first oral drug for treatment of spinal muscular atrophy

FDA approves first oral drug for treatment of spinal muscular atrophy

Researchers develop new therapeutic approach to treat CLN3 Batten disease

Researchers develop new therapeutic approach to treat CLN3 Batten disease

C-Path gets positive response from FDA for drug-induced skeletal muscle injury safety biomarkers

C-Path gets positive response from FDA for drug-induced skeletal muscle injury safety biomarkers

New editorial published following adverse events of gene therapy clinical trial

New editorial published following adverse events of gene therapy clinical trial